• Latest Oral Insulin Drug Making Its Way To Clinical Trials

    Clinical Research News | More than a century has passed since the discovery of insulin, the world's first life-saving treatment for diabetes, and it is still being delivered via injection despite several brushes with success in developing an oral version of the drug. Hope is again on the horizon with the emergence of an oral nanotherapeutic formulation of insulin that comes with the possibility of reducing if not eliminating hypoglycemic events.

    Mar 20, 2024
  • Discussions Begin On Properly Using Generative AI In Clinical Trials

    Clinical Research News | The question of whether generative artificial intelligence (AI) can play a role in clinical trials needs to be supplanted by questions of where and when it should be applied, according to a panel of experts speaking at last month’s Summit for Clinical Ops Executives (SCOPE) in Orlando.

    Mar 19, 2024
  • Navigating Wearable Integration: Key Operational Considerations in Clinical Trials

    Clinical Research News | Wearable devices are helping to transform the way clinical development programs are conducted, offering an innovative approach to data collection, patient monitoring, and endpoint measurement. The seamless integration of wearable technologies into trials requires meticulous consideration across various operational aspects.

    Mar 15, 2024
  • Site Selection With Data-Driven Decisions

    Clinical Research News | Finding the right trial site with access to a diverse patient population is challenging. While the clinical trial and research fields have made great efforts to overcome these challenges, there are still obstacles that slow down the process and frustrate researchers.

    Mar 13, 2024
  • New Vaccinology Rulebook Needed To Outsmart ‘Part-Time Pathogens’

    Clinical Research News | Researchers at University of California San Diego School of Medicine have found that the rules of vaccinology need to be reversed for Staphylococcus aureus (SA), the common and sometimes dangerous bacteria that humans encounter shortly after birth and are continuously exposed to for the remainder of their life.

    Mar 12, 2024
  • Study Establishes ENPP1 As A Biomarker For Immunotherapy Benefit

    Clinical Research News | Researchers in California have shown that breast cancer patients with RNA expression levels of ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1) in the bottom 50th percentile can confidently be treated with Keytruda (pembrolizumab) as well as surgery.

    Mar 7, 2024